New advice from the SMC

The Scottish Medicines Consortium has issued its latest set of recommendations on the use of new medicines within NHS Scotland.

SMC accepted linaclotide for restricted use because the balance of costs and benefits meant that it was considered value for  money.
SMC accepted linaclotide for restricted use because the balance of costs and benefits meant that it was considered value for money.
One medicine was approved for restricted use:
  • Linaclotide (Constella), for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. Its use should be restricted to patients who have not responded adequately to or cannot tolerate all other suitable treatment options.

Two medicines were rejected:

  • Fluocinolone intravitreal implant (Iluvien), for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.
  • Ivacaftor (Kalydeco), for the treatment of cystic fibrosis in patients aged 6 years and older who have a G551D mutation in the CFTR gene.

Further information: Scottish Medicines Consortium

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more